Website Statement

The New York Times paints a misleading picture of the valuable work ExThera does and the appropriate way we do it. At ExThera, we are very proud of our long record of scientific and medical innovation and our work in support of public health. We strongly refute the characterization of our company in this article and wish to restate who ExThera is and the actions we have taken:

 

  • Since 2007, ExThera has been developing and delivering technologies that help address unmet medical need.
  • ExThera does not treat patients. Our products should be used only by licensed clinicians practicing in accordance with applicable medical regulations.
  • The Seraph 100 was CE marked and approved in the EU in 2019 for the treatment of patients with blood stream infections and authorized by the US Food and Drug Administration under an Emergency Use Authorization in 2020 to treat patients with COVID-19 infections.
  • The device has been used safely in thousands of such patients across multiple countries on two continents.
  • Seraph 100 is approved for extracorporeal pathogen and circulating tumor cell removal in Antigua.
  • ExThera has terminated its relationship with Quadrant Clinical Care.
  • John Preston is no longer a member of ExThera’s Board of Directors.
  • Dr. Sanja Ilic is no longer an ExThera employee.